It seems that transcriptional activity and structural property of the fused promoter constitutes the underlying factor for the clinical variability in most features of AEXS except for FSH-dominant hypogonadotropic hypogonadism. The gene discussed is BRD2; the disease is hypogonadotropic hypogonadism.